Guardant Health Inc (NASDAQ: GH) on Monday, plunged -3.88% from the previous trading day, before settling in for the closing price of $64.22. Within the past 52 weeks, GH’s price has moved between $20.14 and $68.00.
A company in the Healthcare sector has dropped its sales by -33.61% annually for the last half of the decade. The company achieved an average annual earnings per share of 12.23%. With a float of $119.11 million, this company’s outstanding shares have now reached $124.48 million.
In an organization with 2021 employees, it is important to assess its efficiency.
Guardant Health Inc (GH) Insider and Institutional Ownership
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Guardant Health Inc is 4.48%, while institutional ownership is 100.08%. The most recent insider transaction that took place on Sep 17 ’25, was worth 6,453. In this transaction Director of this company sold 116 shares at a rate of $55.63, taking the stock ownership to the 7,591 shares. Before that another transaction happened on Sep 17 ’25, when Company’s Director sold 26 for $55.63, making the entire transaction worth $1,446. This insider now owns 18,281 shares in total.
Guardant Health Inc (GH) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.45 earnings per share (EPS) for the period topping the consensus outlook (set at -0.6) by 0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.33% during the next five years compared to -33.61% drop over the previous five years of trading.
Guardant Health Inc (NASDAQ: GH) Trading Performance Indicators
Guardant Health Inc (GH) is currently performing well based on its current performance indicators. A quick ratio of 3.35 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.35, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -2.74 in one year’s time.
